Martin Edelman, MD, Talks About Improving Outcomes in the Management of NSCLC
Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC). "I think that by utilizing these various clinical as well as biological markers, we can develop therapies that are tailored to the individual patient and have substantial evidence to support their use," said Dr Edelman.
This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.
Panelists discussed the price of pharmaceuticals and controlling the cost of care at the 64th Annual Roy A. Bowers Pharmaceutical Conference: A Measured Approach—Health Care Delivery and Transformation in a Metric Driven World, held by Rutgers University.
From the youngest patients to the oldest, the Affordable Care Act’s promise that care will be provided despite pre-existing conditions is bumping against the challenge of keeping costs in check. From around the country come reports of pushback, which evoke the 1990s stories of managed care’s debut: limited choice.
The era of accountable care and pay for performance is here, and physicians will have to embrace these novel reimbursement models. In a plenary session, Rubin Cohen, MD, FCCP, a member of the American College of Chest Physician’s quality improvement committee, discussed the relationship between quality improvement and outcomes.
A symposium on idiopathic pulmonary fibrosis (IPF), which was presented on behalf of InterMune, Inc, highlighted clinical data supporting the use of pirfenidone in patients with IPF. Leading the panel discussion was Steven Nathan, MD, FCCP, a principal investigator involved in studies of pirfenidone. Dr Nathan was joined by IPF experts Lisa Lancaster, MD, of Vanderbilt University Medical Center and Marilyn Glassberg, MD, of the University of Miami Health System.
bioTheranostics, Inc’s Breast Cancer Index, a genomic test quantifying the risk of breast cancer recurrence and predicting which patients will likely benefit from extended endocrine therapy, will be covered by Medicare.